MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

Search

Quanterix Corp

Deschisă

SectorSănătate

6.3 -2.78

Rezumat

Modificarea prețului

24h

Curent

Minim

6.28

Maxim

6.42

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+16.1% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

80M

318M

Deschiderea anterioară

9.08

Închiderea anterioară

6.3

Sentimentul știrilor

By Acuity

50%

50%

149 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 dec. 2025, 22:03 UTC

Principalele dinamici ale pieței

Mining Stocks Slip Near the End of Stellar Year

29 dec. 2025, 15:57 UTC

Principalele dinamici ale pieței

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 dec. 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29 dec. 2025, 23:38 UTC

Achiziții, Fuziuni, Preluări

Manus: Will Continue to Operate From Singapore

29 dec. 2025, 23:38 UTC

Achiziții, Fuziuni, Preluări

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 dec. 2025, 23:37 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms: Will Integrate Manus Service Into Products

29 dec. 2025, 23:36 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 dec. 2025, 23:36 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 dec. 2025, 23:35 UTC

Achiziții, Fuziuni, Preluări

Manus to Join Meta Platforms

29 dec. 2025, 21:33 UTC

Achiziții, Fuziuni, Preluări

Origin: Raise Values Kraken at US$8.65 Billion

29 dec. 2025, 21:33 UTC

Achiziții, Fuziuni, Preluări

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 dec. 2025, 21:31 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 dec. 2025, 21:31 UTC

Achiziții, Fuziuni, Preluări

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

Origin's Kraken Stake to Remain at 22.7%

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

Origin: Additional Interest Offsets Dilution From Raise

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 dec. 2025, 21:29 UTC

Achiziții, Fuziuni, Preluări

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 dec. 2025, 21:29 UTC

Achiziții, Fuziuni, Preluări

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 dec. 2025, 21:29 UTC

Achiziții, Fuziuni, Preluări

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 dec. 2025, 21:27 UTC

Achiziții, Fuziuni, Preluări

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 dec. 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 dec. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 dec. 2025, 20:02 UTC

Achiziții, Fuziuni, Preluări

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 dec. 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

16.1% sus

Prognoză pe 12 luni

Medie 7.5 USD  16.1%

Maxim 8 USD

Minim 7 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

149 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat